ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors // Chi-Med
News Archive
Previous Article   |   Next Article
Presentations | 3 Jun 2014

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors